DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rmls76/investigation) has announced the addition of the "Investigation Report on China Rivaroxaban Market, 2010-2019" report to their offering.
According to some experts, rivaroxaban and dabigatran are the most promising antithrombotic agents which will add a new milestone to the development of cardiovascular drugs. Rivaroxaban is the first available orally active direct factor Xa inhibitor developed by Bayer/ Johnson & Johnson. In Oct. 2008, rivaroxaban was approved to come into the Canada and the EU market under the trade name of Xarelto while on Jul. 1, 2011, it was approved by FDA to enter the American market. Rivaroxaban has been approved by more than 100 countries in the world and succeeded in entering over 75 countries. According to the statistics of Bayer/ Johnson & Johnson, the sales value of rivaroxaban in the world exceeded USD 2.124 billion in 2013, increasing by 219% compared with last year.
After rivaroxaban entering the Chinese market under the trade name of Xarelto in the latter half of 2009, it develops fast with annual sales rising from less than CNY 20 million in 2010 to CNY 140 million in 2014 and CAGR reaching up to over 70% during the period of 2010-2014. Currently, the rivaroxaban market in China has been monopolized by Bayer. The price of rivaroxaban is relatively high for it is imported. The price range of 10 mg rivaroxaban (tablets, 5 tab. per package) is 364.20-388.68 CNY/package in sample hospitals with cities differing slightly in its price. Some Chinese enterprises have been developing the generic drugs of rivaroxaban. And it is estimated that the market size of rivaroxaban in China will keep expanding in the next few years.
Key Topics Covered:
1 Related Concepts of Rivaroxaban
2 Market Profile of Rivaroxaban in China
3 Survey on Sales Status of Rivaroxaban in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Rivaroxaban in China, 2010-2014
5 Survey on Dosage Forms of Rivaroxaban in China, 2010-2014
6 Reference Price of Rivaroxaban in Chinese Hospitals in 2014
7 Major Manufacturers of Rivaroxaban in Chinese Market, 2010-2014
8 Market Outlook of Rivaroxaban in China, 2015-2019
Companies Mentioned
- Bayer AG (Germany)
- Bayer HealthCare
For more information visit http://www.researchandmarkets.com/research/rmls76/investigation
